Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow® assay? Role of haematocrit and haemoglobin levels

被引:28
|
作者
Voisin, Sophie [1 ,2 ]
Bongard, Vanina [2 ,3 ]
Tidjane, Mohammed A. [2 ,4 ]
Lhermusier, Thibault [2 ,4 ]
Carrie, Didier [2 ,4 ]
Sie, Pierre [1 ,2 ,5 ]
机构
[1] CHU Toulouse, Haematol Lab, Toulouse, France
[2] Univ Toulouse 3, F-31062 Toulouse, France
[3] CHU Toulouse, Dept Epidemiol, Toulouse, France
[4] CHU Toulouse, Dept Cardiol, Toulouse, France
[5] CHU Toulouse, INSERM, U1048, Toulouse, France
关键词
VerifyNow (R); P2Y(12) assay; haematocrit; haemoglobin; PERCUTANEOUS CORONARY INTERVENTION; OF-CARE ASSAY; PLATELET REACTIVITY;
D O I
10.1160/TH11-01-0046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The results of the whole blood VerifyNow (R) P2Y(12) assay can be expressed as platelet reaction units (PRU) or % inhibition index ((%)inh), but an optimal cut-off for the assessment of high on-treatment platelet reactivity (HPR) predictive of clinical events has been validated only for PRU. The aim of the study was to study the influence of haematological variables, such as platelet and leukocyte counts or haematocrit / haemoglobin, within the limits indicated by the manufacturer for assay validity, on the results of the test. We performed a comparison of PRU and (%)inh in a series 186 samples obtained from a clinical trial on patients under dual antiplatelet therapy. The results show that PRU significantly decreases with increasing haematocrit / haemoglobin, whereas (%)inh does not, due to a parallel change in PRU and iso-TRAP baseline value. PRU and % inhibition index are not equivalent for the definition of HPR, because of their different sensitivities to haematocrit / haemoglobin.
引用
收藏
页码:227 / 229
页数:3
相关论文
共 50 条
  • [31] P2Y12 Inhibition in Patients with NSTEMI - Can Later Be Better?
    Keaney, John F., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11): : 1056 - 1057
  • [32] The effect of P2Y12 receptor inhibition in chronic inflammatory pain
    Beko, Katinka
    Denes, Adam
    Horvath, Gergely
    Sperlagh, Beata
    SPRINGERPLUS, 2015, 4
  • [33] P2Y12 inhibition after thrombotic thrombocytopenic purpura remission
    Kahraman, Serkan
    Ziyrek, Murat
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 17 (05):
  • [34] Optimizing platelet P2Y12 inhibition for patients undergoing PCI
    Steinhubl, Steven
    Roe, Matthew T.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (02): : 188 - 203
  • [35] P2Y12 inhibition provides cardioprotection similar to ischemic preconditioning
    Korpi, A
    Benanti, A
    Briones, S
    Nagira, T
    Husain, QM
    Thorpe, P
    Gaudette, GR
    Krukenkamp, IB
    CIRCULATION, 2005, 112 (17) : U390 - U390
  • [36] P2Y12 receptor inhibition and LPS-induced coagulation
    Essex, David W.
    Rao, A. Koneti
    CLINICAL SCIENCE, 2016, 130 (06) : 441 - 442
  • [37] More transparency for a therapeutic window in platelet P2Y12 inhibition?
    Storey, Robert F.
    EUROPEAN HEART JOURNAL, 2015, 36 (27) : 1714 - 1717
  • [38] Platelet P2Y12 receptor inhibition by thienopyridines: status and future
    Porto, Italo
    Giubilato, Simona
    De Maria, Giovanni Luigi
    Blasucci, Luigi Marzio
    Crea, Filippo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1317 - 1332
  • [39] Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies
    Jeong, Young-Hoon
    Bliden, Kevin P.
    Antonino, Mark J.
    Park, Ki-Soo
    Tantry, Udaya S.
    Gurbel, Paul A.
    AMERICAN HEART JOURNAL, 2012, 164 (01) : 35 - 42
  • [40] P2Y12 INHIBITION IN ACS: PLATELET AND BEYOND PLATELET EFFECTS
    Badimon, L.
    Mendieta, G.
    Casani, L.
    Vilahur, G.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 23 - 23